IPO

Gland Pharma Limited IPO

Mainboard

Pharmaceuticals & Drugs

Listed On: Nov 20, 2020 at ₹ 1710.0

₹ 15000 /10 Shares

Check Allotment

09 Nov, 2020

Open Date

11 Nov, 2020

Close Date

18 Nov, 2020

Allotment Date

20 Nov, 2020

Listing Date
Price Summary

Last Closing

1,676.00 (11.73%)

52 Week High

2,131.00

52 Week Low

1,277.80

Last Update

19-Dec-2025 3:30 PM
Expected Premium
+ ₹50 (3.33%)

*Expected Premium provided in this app is derived from market rumors. It is not a guaranteed indicator of the actual listing price and should be interpreted with caution.

IPO Live Subscription Details
QIB 6.40x
Retail 0.24x
NIIs 0.51x
Retail 0.24x
Total 2.06x
Last updated: 2020-11-11 17:00:00
IPO Issue Details
  • Issue Price ₹1490 - 1500 per equity share
  • Face Value ₹1 Per Equity Share 
  • Issue Price 43,196,968 Eq Shares of ₹1 (aggregating up to ₹6,479.55 Cr)

    Fresh Issue:8,333,333 Eq Shares of ₹1 (aggregating up to ₹1,250.00 Cr)

    Offer for Sale: 34,863,635 Eq Shares of ₹1 (aggregating up to ₹5,229.55 Cr)
  • Listing at BSE, NSE
  • List Price 1710.0
  • Listing Date 2020-11-20
  • Lead Manager Citigroup Global Markets India Private Limited
    Haitong Securities India Private Limited
    Kotak Mahindra Capital Company Limited
    Nomura Financial Advisory And Securities (India) Pvt Ltd
  • Registrar Link Intime India Private Ltd
IPO Details
  • Retail Portion N/A
IPO Documents
DRHP
RHP
IPO Details


The IPO of is priced at ₹1490 - 1500 per equity share, which has a face value of ₹1 Per Equity Share  each, IPO bidding starts from Nov 9, 2020 and ends on Nov 11, 2020. The allotment for IPO will be finalized on Nov 18, 2020. IPO will be listed on BSE, NSE, with a tentative listing date fixed as Nov 20, 2020. The company shall list its equity shares on the BSE, NSE. Link Intime India Private Ltd is the registrar of the issue.

The book-running lead manager for the IPO is/are Citigroup Global Markets India Private Limited, Haitong Securities India Private Limited, Kotak Mahindra Capital Company Limited, Nomura Financial Advisory And Securities (India) Pvt Ltd.


The IPO sets its price band at 1490 - 1500 for each share. A single application for Gland Pharma Limited IPO must contain at least 10 shares.

Read More
IPO Subscription Analysis And Details
Retail
0.24x
QIB
6.40x
NII
0.51x
Total
2.06x
As on QIB NII Retail Total
Shares Offered / Reserved 8,639,394 6,479,546 15,118,939 27,350,957
Day 1 09-11-20 05:00 PM
0.00 x 0.01 0.08 x 0.05 x
Day 2 10-11-20 05:00 PM
0.48 x 0.03 0.15 x 0.22 x
Day 3 11-11-20 06:00 PM
6.40 x 0.51 0.24 x 2.06 x
Valuations
Earnings Per Share (EPS) N/A
P/E Ratio N/A
RoNW N/A
Net Asset Value (NAV) - Post Issue N/A
Company Financials
In Crs.
In Cr.
31-Mar-20 31-Mar-19 31-Mar-18
Assets 4,086.03 3,523.54 2.929.46
Revenue 2,772.40 2,129.76 1,671.68
Profit After Tax 772.85 451.85 321.05
About Company

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets.

They operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped them witness exponential growth.

They are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

Read More
IPO - Issue Objectives
1

To finance the incremental working capital requirements of our Company

2

To meet funding requirements for capital expenditure requirements

3

To meet the general corporate purposes